December 5, 2024 7:42am
Investors wait again for economic data releases; Initial jobless claims data tomorrow and nonfarm payrolls data for November due Friday
News: bluebird bio (BLUE closed at $0.3778 or -105.38% and down -$0.25 or -33.45% in aftermarket) will proceed with a 1-for-20 reverse stock split (RSS) approved by both its BOD and BLUE stockholders; the primary goal of the RSS is to increase the per share market price of the stock to regain compliance for the Nasdaq’s continued listing.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
MY Pre-Open Thoughts: 4 Negative and 1 Positive Indications
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Wednesday’s night’s … RegMed Investors (RMi) Closing Bell: back to musical sector equity chairs … https://www.regmedinvestors.com/articles/13721
Thursday: The pre-open Dow futures are DOWN -0.03% or (-12 points), the S&P futures are DOWN -0.04% or (-2 points) and the Nasdaq futures are DOWN -0.05% or (-11 points)
- U.S. stock futures were thinly down, Thursday
- European stocks were higher,
- Asia-Pacific markets traded mixed
Henry’omics: We need to more than consider the economic environment to comprehend the micro/macro re “our” universe of cell and gene therapy companies
During Wednesday’s trading session, the 3 major indexes saw solid gains, with the S&P 500 and Nasdaq scored new closing records.
Wednesday: The Dow closed UP +308.51 points or +0.69%, the S&P closed UP +36.61 points or +0.61% while the Nasdaq closed UP +254.21 points or +1.30%
- Tuesday’s advance/decline line ended with a negative close at the close of 11 incliner, 21 decliners and 3 flats
Economic Data Docket: Challenger jobs cuts, year-over-year, November (+50.9% previously); Initial jobless claims, week ending Nov. 30 (213,000 previously)
Q4/24: 2 negative and 1 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive Indications:
Wednesday, Tuesday, Monday, Friday, Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
CRISPR Therapeutics (CRSP) closed down -$0.10 after Tuesday’s -$3.91, Monday’s +$3.98, Friday’s +$0.33 and last Thursday with a positive +$0.25 or +0.49% pre-open
Negative Indications:
Wednesday, Tuesday, Monday, Friday and last Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Alnylam Pharmaceuticals (ALNY) closed up +$2.88 after Tuesday’s -$1.17, Monday’s -$0.06 and Friday’s -$0.67 with a negative -$2.60 or -1.02% pre-open
BioLife Solutions (BLFS) closed down -$0.43 with a negative -$0.58 or 2.20% pre-open
bluebird bio (BLUE) closed up at $0.3778 and down -$0.25 or -33.45% aftermarket after reverse split (in news) pre-open
Mesoblast (MESO) closed down -$0.50 after Tuesday’s +$0.23 with a negative -$0.73 or -6.38% pre-open
The BOTTOM LINE: Trending or bending? …. A little bit of each!
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Portfolio managers are addressing rotations as December “shakes” to years-end.
- I keep writing about uncertainty and skepticism … and coming realities.
- Even with the potential for some market hiccups along the way, the good news is Q4 has historically skewed positively, even as sector earnings kicked the bucket down the road!
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
